Targeting ligand-activated ErbB2 signaling inhibits breast and prostate tumor growth.
Explore this paper's citation graph
Summary
It is demonstrated that the in vitro and in vivo growth of several breast and prostate tumor models is inhibited by 2C4 treatment, which sterically hinders ErbB2's recruitment intoErbB ligand complexes.
- Type
- letter
- Published
- 2002-08-01
- Cited by
- 910
- References
- 87
- Access
- Open access
- OpenAlex
- https://openalex.org/W2014457594
- Semantic Scholar
- https://api.semanticscholar.org/CorpusID:23846091
Keywords
Cancer research, Prostate, Ligand (biochemistry), Signal transduction, Prostate cancer
References
- Binding Interaction of the Heregulinβ egf Domain with ErbB3 and ErbB4 Receptors Assessed by Alanine Scanning Mutagenesis*
- Stromal-epithelial interactions in breast cancer.
- EGF receptor signaling in prostate morphogenesis and tumorigenesis.
- Intracellular expression of single chain antibodies reverts ErbB-2 transformation.
- Heregulin‐dependent regulation of HER2/neu oncogenic signaling by heterodimerization with HER3.
- Growth regulation of human breast and ovarian tumor cells by heregulin: Evidence for the requirement of ErbB2 as a critical component in mediating heregulin responsiveness.
- HER-2/neu (p185neu) protein expression in the natural or treated history of prostate cancer.
- A mechanism for hormone-independent prostate cancer through modulation of androgen receptor signaling by the HER-2/neu tyrosine kinase
- Diversification of Neu differentiation factor and epidermal growth factor signaling by combinatorial receptor interactions.
- ErbB‐2 is a common auxiliary subunit of NDF and EGF receptors: implications for breast cancer.
- CWR22: the first human prostate cancer xenograft with strongly androgen-dependent and relapsed strains both in vivo and in soft agar.
- Cooperative signaling of ErbB3 and ErbB2 in neoplastic transformation and human mammary carcinomas.
- The epidermal growth factor receptor: from mutant oncogene in nonhuman cancers to therapeutic target in human neoplasia.
- Recombinant humanized anti-HER2 antibody (Herceptin) enhances the antitumor activity of paclitaxel and doxorubicin against HER2/neu overexpressing human breast cancer xenografts.
- Analysis of heregulin-induced ErbB2 phosphorylation with a high-throughput Kinase receptor activation enzyme-linked immunosorbant assay.
- Untangling the ErbB signalling network
- The ErbB-2/HER2 oncogenic receptor of adenocarcinomas: from orphanhood to multiple stromal ligands.
- Expression and gene copy number analysis of ERBB2 oncogene in prostate cancer.
- From HER2/Neu signal cascade to androgen receptor and its coactivators: a novel pathway by induction of androgen target genes through MAP kinase in prostate cancer cells.
- Epidermal Growth Factor-related Peptides Activate Distinct Subsets of ErbB Receptors and Differ in Their Biological Activities (*)
Cited by
- HER-2/Neu signaling and therapeutic approaches in breast cancer
- Tyrosine kinases as targets for cancer therapy.
- Molecular predictors of response to trastuzumab and lapatinib in breast cancer
- Resistance to HER2-directed antibodies and tyrosine kinase inhibitors
- Dual blockade of HER2 in HER2-overexpressing tumor cells does not completely eliminate HER3 function
- Molecular architecture of the ErbB2 extracellular domain homodimer
- Molecular interactions of ErbB receptor tyrosine kinases - with an outlook on their therapeutic targeting
- Biology of the epidermal growth factor receptor family.
- Potentiation of drug-induced cytotoxicity by conjugated linoleic acids (CLA) in in vitro models of drug-resistant cancer
- Therapeutics: Stop signals
- Targeting ERBB receptors in cancer.
- Novel mutations of epidermal growth factor receptor in localized prostate cancer.
- Pertuzumab and its accelerated approval: evolving treatment paradigms and new challenges in the management of HER2-positive breast cancer.
- Molecular mechanisms involving prostate cancer racial disparity.
- Emerging role of EGFR-targeted therapies and radiation in head and neck cancer.
- Monoclonal antibody therapy for prostate cancer.
- Anti-cancer mechanisms of the natural plant derived compound, Withaferin A in HER-2/neu breast cancer
- Beyond the Canonical Function of Receptor Tyrosine Kinase: New Perspectives for ERBB2 (HER2) Signaling Control Across the Cell Membrane
- Pertuzumab et T-DM1 : de nouvelles perspectives dans le traitement du cancer du sein HER2 positif
- Mechanism of action of anti-HER2 monoclonal antibodies: scientific update on trastuzumab and 2C4.
Related papers
- Identification of a 5-gene signature panel for the prediction of prostate cancer progression
- Androgen Receptor Antagonists for the Treatment of Prostate Cancer
- Dynamic Profiling of Exosomal microRNAs in Blood Plasma of Patients with Castration-Resistant Prostate Cancer.
- Can we improve the detection rate of prostate cancer using standard 12‐core TRUS‐guided prostate biopsy? Focused on the location of prostate biopsy
- Prostate cancers detected on repeat prostate biopsies show spatial distributions that differ from those detected on the initial biopsies
- A Cancer-Indicative microRNA Pattern in Normal Prostate Tissue
- THE EXPRESSIONS OF MITOSIS REGULATIVE FACTOR STK-15 IN PROSTATE CANCER
- CSR1 Suppresses Tumor Growth and Metastasis of Prostate Cancer